US20120329762A1 - Anti-thrombotic compounds - Google Patents

Anti-thrombotic compounds Download PDF

Info

Publication number
US20120329762A1
US20120329762A1 US13/345,360 US201213345360A US2012329762A1 US 20120329762 A1 US20120329762 A1 US 20120329762A1 US 201213345360 A US201213345360 A US 201213345360A US 2012329762 A1 US2012329762 A1 US 2012329762A1
Authority
US
United States
Prior art keywords
clopidogrel
compound
formula
isomers
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/345,360
Other languages
English (en)
Inventor
Ashok Kumar
Satish Rajanikant Soudagar
Nellithanath Thankachen Byju
Gaurav Sahal
Arpana Prashant Mathur
Sanjay Pandurang Gawade
Dinesh Kanji Bhadra
Devki Moje
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipca Laboratories Ltd
Original Assignee
Ipca Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipca Laboratories Ltd filed Critical Ipca Laboratories Ltd
Assigned to IPCA LABORATORIES LIMITED reassignment IPCA LABORATORIES LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: Bhadra, Dinesh Kanji, BYJU, NELLITHANATH THANKACHEN, Gawade, Sanjay Pandurang, KUMAR, ASHOK, Mathur, Arpana Prashant, Moje, Devki, Sahal, Gaurav, SOUDAGAR, SATISH RAJANIKANT
Priority to US13/428,657 priority Critical patent/US8536337B2/en
Publication of US20120329762A1 publication Critical patent/US20120329762A1/en
Priority to US13/957,119 priority patent/US20130316987A1/en
Priority to US13/956,945 priority patent/US20130316986A1/en
Priority to US14/045,430 priority patent/US10105353B2/en
Priority to US14/045,505 priority patent/US20140038924A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Definitions

  • the present invention relates to anti-thrombotic compounds, specifically substantially pure isomer of an intermediate metabolite of clopidogrel, namely, (7aS,2′S)-2-oxoclopidogrel and its pharmaceutically acceptable salts thereof.
  • the present invention also relates to a method of ameliorating the drawbacks of the anti-platelet drug, clopidogrel, said method comprises administration of isolated substantially pure isomer of (7aS,2′S)-2-oxoclopidogrel in its free or pharmaceutically acceptable salt form for alleviating the symptoms of thrombosis and/or embolism by inhibiting blood platelet aggregation.
  • Intravascular thrombosis and embolism are common clinical manifestations of many diseases. Unregulated activation of the hemostatic system has the potential to cause thrombosis and embolism, which can reduce blood flow to critical organs like the brain and myocardium.
  • Certain patient groups have been identified that are particularly prone to thrombosis and embolism. These include patients (1) immobilized after surgery, (2) with chronic congestive heart failure, (3) with atherosclerotic vascular disease, (4) with malignancy, or (5) who are pregnant.
  • thrombosis prone individuals have no identifiable hemostatic disorder, although there are certain groups of individuals having inherited or acquired “hypercoagulable” or “prethrombotic” conditions predisposing them to recurrent thrombosis (Harrison's Principles of Internal Medicine, 12th ed. McGraw Hill).
  • hemostatic plugs As the primary hemostatic plug is being formed, plasma coagulation proteins are activated to initiate secondary hemostasis. There is little difference between hemostatic plugs, which are a physiological response to injury, and pathologic thrombi. Thrombosis is often described as coagulation which has occurred in the wrong place or at the wrong time. Hemostatic plugs or thrombi that form in veins where blood flow is slow are richly endowed with fibrin and trapped red blood cells and contain relatively few platelets. These thrombi often form in leg veins and can break off and embolize to the pulmonary circulation. Conversely, clots that form in arteries under conditions of high flow are predominantly composed of platelets and have little fibrin.
  • Extracellular nucleotides and their receptors of platelets are important components of the cardiovascular system and are involved in functions like platelet activation and the control of vascular tone.
  • Adenosine diphosphate (ADP) and Adenosine Triphosphate (ATP) are playing crucial roles in the physiological process of haemostasis and in the development and extension of arterial thrombosis (2).
  • ADP is a weak agonist of platelet aggregation inducing only reversible responses as compared to strong agonists such as thrombin or collagen.
  • ADP is an important so-called secondary agonist which amplifies most of the platelet responses and contributes to the stabilization of the thrombus.
  • the receptors for extracellular nucleotides belong to the P2 family which consists of two classes of membrane receptors: P2X ligand-gated cation channels (P2X1-7) and Glycoprotein-coupled P2Y receptors (P2Y1,2,4,6,11,12,13,14). Each of these receptors has a specific function during platelet activation and aggregation, which naturally has implications for their involvement in thrombosis.
  • the P2Y12 receptor is an established target of antithrombotic drugs mainly the thienopyridine class of compounds like ticlopidine, clopidogrel, prasugrel etc. . . .
  • the mainstay of antiplatelet therapy for patients with acute coronary syndromes is administration of a combination of Aspirin and clopidogrel.
  • Aspirin inhibits platelet thomboxane A2 production and platelet activation, and reduces the risk of recurrent ischemic events in patients at high risk of vascular events by 22% (absolute risk reduction (ARR) about 2%) at the expense of an increase in the odds of major bleeding events by about 60% (Absolute risk increase (AR1) about 0.5%.
  • Clopidogrel inhibits ADP induced platelet activation by blocking the platelet receptor P2Y12, which when combined with Aspirin therapy in patients with ACS, reduces the risk of recurrent ischemic events by a further 20% (ARR about 2.1%), in which the major bleeding events are not increased statistically from aspirin monotherapy.
  • Clopidogrel (Formula I), chemically named as “′(+)-(S)-methyl 2-(2-chlorophenyl)-2-(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)acetate”, is currently considered to be the gold standard in the inhibition of blood platelet aggregation.
  • Clopidogrel is marketed as its hydrogen sulphate, hydrochloride, and benzene sulphonate salts. It is widely used for controlling the ischemic events and other cardiovascular disorders efficiently for last 12 years or more.
  • clopidogrel has several potential limitations. First, the onset of action is delayed and a time lag between administration and therapeutic activity is observed. A therapeutically significant level of 50% inhibition of ADP induced platelet aggregation, as measured by light transmission aggregometry (LTA) (5 ⁇ M ADP ex-vivo) is not reached until 4-6 hours after administration of a loading dose of 300 mg clopidogrel or until 2 hours by doubling the dose to 600 mg.
  • LTA light transmission aggregometry
  • prasugrel Treatment of patients with a recently approved drug, namely, prasugrel rendered them susceptible to bleeding episodes, which may be life threatening, restricting its application in patients having a body weight of less than 60 kg and age of more than 75 years.
  • Prasugrel has also been found to increase liver disease/toxicity in patients who are at risk of cirrhosis and thus pharmacovigilance is suggested by FDA and is also a suspected carcinogen.
  • clopidogrel is comparatively safer, resulting generally in lesser bleeding and liver toxicity.
  • (2′S)-2-oxo-clopidogrel is an intermediate metabolite formed during the oxidative metabolic step, as shown in above scheme.
  • the active metabolite of clopidogrel has the structure given in formula III, and it has been documented that only one of the isomer is found to inhibit platelet, however, its absolute configuration is not yet determined.
  • Active metabolite of 4R,1′S-isomer is reported in literature (Hagihara et al, Drug Metab. Pharmacokinet 23 (6): 412-420 (2008) & Proceedings of the 54th ASMS Conference on Mass Spectrometry and Allied Topics, 2008).
  • 2-oxo-clopidogrel takes the structural formula II, it generates one additional chiral centre at position 7a and thus making it possible to exist in 2 different chiral isomers.
  • the chiral centre will get disrupted and racemization of 2-oxoclopidogrel at 7a position is expected, which will result compound of formula II to exists as mixture of isomers.
  • prasugrel metabolic pathway is elaborated in detail in literature (ref: Farid et al, Drug metabolism and disposition, 2007, vol. 35, p. 1096-1104), which provides additional information on the possible metabolic pathways for the isomers of Formula II, VI, and VII, and revealed that the active metabolite generated from formula II only exhibits pharmacological activity.
  • the present inventors have discovered that the use of clopidogrel presents substantial clinically significant limitations in inhibiting rapid platelet aggregation safely in a consistent manner for reasons as detailed above, though it is considered to be the gold standard among anti-platelet medicine available today.
  • the invention therefore, aims to provide new substances for treatment/prophylaxis of thrombosis and embolism, as well as compositions for use in such treatment, which ameliorate at least one of the clinical drawbacks of clopidogrel discussed above.
  • the isolated isomer remains stable and does not convert into (7aR,2′S)— isomer under normal conditions, through keto-enol tautomerism and/or equilibration.
  • the compound of the present invention shows only insignificant conversion into the mixture of isomers under normal conditions even in solutions.
  • the present invention provides isomerically enriched & substantially pure isolated (7aS,2′S)-2-oxo-clopidogrel ⁇ chemical Name: Methyl (7aS,2′S)-2-(2-chlorophenyl)-2-(2,4,5,6,7,7a-hexahydrothieno[3,2-c]-5-pyridin-2-one)acetate ⁇ and its pharmaceutically acceptable salts for pharmaceutical application.
  • the compound of the present invention is substantially stable to manufacture in substantially pure state and also for the manufacture of drug products (formulations) for long term storage and pharmaceutical use.
  • the compound of the present invention is substantially free of other isomers for example, compound of Formula VI, and Formula VII, apart from isomer of Formula IIB. Substantially free herein means the levels of these compounds individually or cumulatively are less than 10%, preferably less than, 5%, more preferably less than 3%, still more preferably, less than 1.0%.
  • the present invention includes a new method of synthesizing substantially pure isomer of (7aS,2′S)-2-oxoclopidogrel from a mixture of isomers obtained by a chiral selective synthesis comprising treating said mixture of isomers with an acid like sulphuric acid, sulphonic acids such as methane sulphonic acid, benzene sulphonic acid etc., and selectively crystallizing the compound of the present invention.
  • the crystallization of the (7aS,2′S)-isomer may be carried out with sequential or simultaneous conversion of the (7aR,2′S)-isomer or without the transformation of the unwanted (7aR,2′S)-isomer.
  • the isomer is produced with fully conservation of stereoconfiguration in solid form.
  • the selectively precipitated salt may be used as such for pharmaceutical preparations or may be neutralized with suitable base to obtain the isomerically pure compound in free form.
  • the mixture of (7aS,2′S)/(7aR,2′S) isomers may be treated in a polar organic solvent(s) and allowed to selectively crystallize pure (7aS,2′S)-isomer, by optional seeding of crystals of pure isomer, and isolating crystalline compound as pure isomer.
  • the crystallization of the (7aS,2′S)-isomer be carried with sequential or simultaneous conversion of the (7aR,2′S)-isomer or without the transformation of the unwanted isomer.
  • (7aS,2′S)-2-oxoclopidogrel is isolated in substantially pure form in its free base form, which may be converted to a pharmaceutically acceptable salt by treating with a suitable acid.
  • the invention also provides a method of treatment and/or prophylaxis of thrombosis and/or embolisms in a patient in need of such treatment, comprising administering an amount of isolated (7aS,2′S)-2-oxo-clopidogrel or a pharmaceutically acceptable salt thereof, while avoiding and/or alleviating the side effects associated with the clopidogrel acid metabolite of Formula IV, Formula VI, or VII which otherwise was impossible without the advent of the compound of the present invention.
  • the method achieves a therapeutic effect substantially greater to that observed following the administration of a substantially higher dose of clopidogrel due to the elimination of unwanted metabolic products and other isomers in the administration of clopidogrel.
  • the method results in the in vivo formation of the active metabolite of clopidogrel at a concentration greater than or equivalent that observed following administration of a substantially higher dose of clopidogrel.
  • the onset of therapeutic action upon administration of isolated substantially pure (7aS,2′S)-2-oxoclopidogrel is at least 50% more rapid than that observed following administration of a substantially higher dose of clopidogrel.
  • various amounts of the isolated (7aS,2′S)—2-oxoclopidogrel or a pharmaceutically acceptable salt thereof may be administered.
  • the amount administered may be 20 to 40 mg and the substantially higher dose of clopidogrel may be 300 mg.
  • the amount of substantially pure (7aS,2′S)—2-oxoclopidogrel or a salt thereof may be 35 to 80 mg and wherein the equivalent substantially higher dose of clopidogrel may be 600 mg.
  • the amount of substantially pure (7aS,2′S)-2-oxoclopidogrel or a salt thereof may be 50 to 100 mg and the substantially higher dose of clopidogrel may be 900 mg.
  • the amount of substantially pure isolated (7aS,2′S)—2-oxoclopidogrel or a salt thereof may be 3 to 15 mg and the substantially higher dose of clopidogrel may be 75 mg.
  • the amount of substantially pure (7aS,2′S)-2-oxoclopidogrel or a salt thereof may be 6 to 20 mg and the substantially higher dose of clopidogrel may be 150 mg. It should be understood that different salts of compound of the formula may have different molecular weights and therefore for the purposes of dose calculation, it is based on the amount of non-salt form of the compound (i.e. base).
  • a higher loading dose may be followed by one or more maintenance doses.
  • a loading dose of 20-60 mg substantially pure (7aS,2′S)-2-oxoclopidogrel or a salt thereof may be administered to a patient resulting in greater than 50% inhibition of ADP induced human blood platelet aggregation in most patient population.
  • this, or an alternative loading dose may be followed with a maintenance dose of 3-15 mg substantially pure (7aS,2′S)-2-oxoclopidogrel or a salt thereof, is administered to a patient, resulting in greater than 50% inhibition of ADP induced human blood platelet aggregation.
  • a method for minimizing inter individual platelet reactivity variability and metabolic loading in the treatment and/or prophylaxis of thrombosis and/or embolisms observed following administration of a dose of clopidogrel comprising administering substantially pure (7aS,2′S)-2-oxoclopidogrel or its pharmaceutically acceptable salt to a patient in need thereof.
  • the inter-individual variability may be due to CYP450 isoforms and its polymorphic manifestations, for example, in the CYP2C19*2 allele or CYP2C19*17 allele. Additionally or alternatively, the inter-individual variability may be due to P-glycoprotein efflux transports.
  • a method for the treatment or prophylaxis of thrombosis or embolisms comprising administration of a substantially pure (7aS,2′S)-oxo-clopidogrel or a pharmaceutically acceptable salt and a proton pump inhibitor.
  • the methods discussed herein may additionally comprise the step of administration of one or more additional therapeutic agents.
  • additional therapeutic agents may include, for example, anti-platelet agents selected from aspirin, cilostazol and dipyridamole.
  • additional agents may be administered simultaneously, sequentially or subsequently or in combination to the principal active ingredient.
  • compositions for use in the methods described herein for use in the methods described herein.
  • an amount of active ingredient as a substantially pure (7aS,2′S)-oxo-clopidogrel or a pharmaceutically acceptable salt, this may be comprised within the composition of this aspect of the invention.
  • a fixed dose composition of a substantially pure (7aS,2′S)-oxo-clopidogrel or a pharmaceutically acceptable salt characterized in that said composition comprises a dose of 1 to 60 mg of substantially pure isomer of 2-oxo-clopidogrel or a salt thereof.
  • the fixed dose composition comprises a dose of a substantially pure (7aS,2′S)-oxo-clopidogrel or a pharmaceutically acceptable salt thereof of 5-30 mg.
  • the fixed dose composition may additionally or alternatively further comprise one or more anti-platelet agents selected from aspirin, cilostazol and dipyridamole.
  • FIG. 1 A representative HPLC chromatogram of (7aS,2′S)-oxo-clopidogrel bisulphate run on Chiralpak AD-H column.
  • FIG. 2 A representative HPLC chromatogram of mixture of (7aS,2′S)/(7aR,2′S)-oxo-clopidogrel base run on Chiralpak AD-H column.
  • FIG. 3 A representative HPLC chromatogram of substantially pure ((7aS,2′S))-oxo-clopidogrel free base run on Chiralpak AD-H column.
  • FIG. 4 A representative HPLC chromatogram of (7aS,2′S)/(7aR,2′S)— oxo-clopidogrel hydrochloride run on Chiralpak AD-H column.
  • FIG. 5 A representative IR spectra of (7aS,2′S)-oxo-clopidogrel free base.
  • FIG. 6 A representative IR spectra of (7aS,2′S)-oxo-clopidogrel bisulphate.
  • FIG. 7 A representative IR spectra of (7aS,2′S)/(7aR,2′S)-oxo-clopidogrel hydrochloride.
  • FIG. 8 A representative powder X-Ray diffraction pattern of substantially pure (7aS,2′S)-oxo-clopidogrel free base.
  • FIG. 9 A representative powder X-Ray diffraction pattern of (7aS,2′S)-oxo-clopidogrel bisulphate.
  • FIG. 10 A representative powder X-Ray diffraction pattern of (7aS,2′S)/(7aR,2′S)-oxo-clopidogrel hydrochloride.
  • FIG. 11 A representative differential scanning calorimetric graph of (7aS,2′S)-oxo-clopidogrel bisulphate.
  • any of the words “including,” “includes,” “comprising,” and “comprises” mean “including without limitation” and shall not be construed to limit any general statement that it follows to the specific or similar items or matters immediately following it.
  • Embodiments of the invention are not mutually exclusive, but may be implemented in various combinations. The described embodiments of the invention and the disclosed examples are given for the purpose of illustration rather than limitation of the invention as set forth the appended claims.
  • the present inventors could resolve single isomer of 2-oxo-clopidogrel substantially free of the counter stereo-isomer of Formula IIB, which can deliver active metabolite of desired absolute configuration more efficiently compared to mixture.
  • the present invention is realized by way of preferential stereoselective crystallization of one of the isomer ⁇ (7aS,2′S)-isomer ⁇ from a mixture of isomers with or without dynamic conversion of counter stereo-isomer ⁇ (7aR,2′S)-isomer ⁇ through enol form.
  • 2-oxo-clopidogrel can exists in three isomeric forms, namely structures of formula II, Formula VI and Formula VII.
  • the compounds of the present invention are substantially free of other isomers for example, compound of Formula VI, and Formula VII, apart from isomer of Formula IIB.
  • Substantially free herein means the levels of these compounds individually or cumulatively are less than 10%, preferably less than, 5%, more preferably less than 3%, still more preferably, less than 1.0%.
  • the present invention provides a method for synthesizing substantially pure (7aS,2′S)-2-oxoclopidogrel.
  • the process comprises first synthesizing mixture of (7aS,2′S)/(7aR,2′S)-2-oxo-clopidogrel through a synthetic route disclosed in our co-pending application.
  • the process according to the invention comprises reacting Methyl(R)-2-(4-nitrophenylsulfonyloxy)-2(2-chlorophenyl)acetate with 5,6,7,7a-tetrahydro-4H-thieno[3,2-c]pyridin-2-one to form a mixture of isomers of compounds of formula IIA & IIB which may contains some amount of compounds of Formula VI and VII, and treating said mixture of isomers with an acid like sulphuric acid, sulphonic acids such as methane sulphonic acid, benzene sulphonic acid etc., and crystallizing the (7aS,2′S)-isomer selectively.
  • the process is established with transformation of the (7aR,2′S)-isomer, so that the inactive isomer can be converted into the active compound and thus recovered for use.
  • the isomer of the invention is produced with fully conservation of stereoconfiguration in solid form.
  • the isomer of the present invention is characterized by its unique superior pharmacological activity. This process enables (7aS,2′S)-2-oxoclopidogrel to isolate directly in its acid salt form, which may be converted into a free base form under suitable reaction conditions.
  • the process of isolation of compound of the present invention may be performed at appropriate temperature, preferably at a temperature from 0 to +30° C.
  • the isomer of the present invention is characterized by its unique pharmacological activity and further structural identification by NMR, and Chiral HPLC from rest of the isomers. It exhibits optical rotation characteristic from the mixture of isomers.
  • the acid is preferably selected from acids such as sulphuric acid or sulphonic acid, for example methane sulphonic acid, benzene sulphonic acid etc.
  • the isolation and stereo-selective conversion is effected in a suitable solvent.
  • the solvent may be selected from organic solvents. Suitable solvents include, polar solvents like, C 1 -C 4 alcohols, esters, and ketones. Exemplary C 1 -C 4 alcohol include, methanol, ethanol, isoproapnol, butanol etc. Exemplary ester solvents include, ethyl acetate, butyl acetate, propyl acetate, etc. Ketones include, but not limited to, acetone, methyl ethyl ketone; and nitriles such as Acetonitrile.
  • a solution of 2-oxo-clopidogrel isomeric mixture is first obtained, and an acid of choice is added to the solution obtained.
  • These steps may be performed under heating or cooling, appropriate for the reaction depending on the choice of solvent and acid used. Temperature of the reaction can range from cold to room temperature.
  • the mixture may be maintained for suitable time, under suitable cooling for sufficient crystals to stereo-selectively precipitates out.
  • the crystallization process is carried out for sufficient period of time to allow complete conversion into the (7aS,2′S)-isomer, suitable for a period of 5 to 20 hours.
  • the mixture of (7aS,2′S)-/(7aR,2′S)-isomers may be treated in a polar organic solvent, and allowed to selectively crystallize the (7aS,2′S)-isomer enabling its isolation as pure isomer.
  • the mixture may be optionally seeded with the substantially pure (7aS,2′S)-isomer free base to facilitate selective crystallization.
  • the crystallization of the (7aS,2′S)-isomer may take place with sequential or simultaneous conversion of the (7aR,2′S)-isomer or without the transformation of the unwanted (7aR,2′S)-isomer.
  • the process is established with transformation of the (7aR,2′S)-isomer, so that the undesired isomer can be converted into the active compound and recovered for use.
  • (7aS,2′S)-2-oxoclopidogrel is isolated in substantially pure form in its free base form.
  • the (7aS,2′S)-2-oxoclopidogrel base may be converted to its pharmaceutically acceptable salt by treatment with suitable acid in an appropriate solvent.
  • the isolation and stereo-selective conversion is effected in a suitable solvent.
  • the solvent found useful are polar organic solvents. Suitable solvents include, Ethyl acetate, Alcohol such as methanol either separately or as mixture.
  • FIG. 1-2 A typical HPLC chromatogram of pure isomer and mixture of isomers are presented in FIG. 1-2 .
  • the X-Ray powder pattern, IR spectra and DSC data are presented in FIGS. 5 to 11 .
  • the compound of Formula II is an intermediate metabolite of clopidogrel.
  • this metabolite and its position in the metabolic pathway of clopidogrel being known for almost 20 years, its use as an active agent for the treatment of thrombosis and/or embolisms has not previously been suggested. This is partly because this metabolite and the one identified as Formula IV in the metabolic pathway mentioned herein before has been found to be inactive.
  • the existence of single isomer was not possible without the advent of the present invention because of the isomeric nature of the oxo-clopidogrel, and its conversion into isomeric mixture of isomers of Formula IIB, VI, and VII.
  • the inventors have now been able to produce a substantially pure (7aS,2′S)-oxo-clopidogrel or a pharmaceutically acceptable salt that can advantageously be administered directly to patients in place of clopidogrel and that this ameliorates some if not all of the disadvantages associated with the use of clopidogrel.
  • a substantially pure (7aS,2′S)-oxo-clopidogrel or a pharmaceutically acceptable salt that can advantageously be administered directly to patients in place of clopidogrel and that this ameliorates some if not all of the disadvantages associated with the use of clopidogrel.
  • the invention provides a method for treatment and/or prophylaxis of thrombosis and/or embolism, where the method comprises administering a predetermined dose of an isolated substantially pure (7aS,2′S)-2-oxo-clopidogrel (Formula IIA) or a pharmaceutically acceptable salt thereof such that it results in the in-vivo formation of the active metabolite of clopidogrel at a concentration equivalent or greater than that achieved through the administration of a substantially greater dose of clopidogrel.
  • the present invention enables a substantial reduction in the dose of active ingredient required for achieving a therapeutic concentration of active metabolite of clopidogrel compared with administration of conventional therapeutic doses of clopidogrel.
  • dose tolerability and efficacy are enhanced significantly.
  • Present invention not only improve the onset of therapeutic action by achieving greater than 50% inhibition of ADP induced platelet aggregation in shorter period and reduces inter individual variability, but also eliminates the side effects associated with the inactive metabolites (for example, Formula IV) and reduces the metabolic load on liver.
  • one or more additional active compounds may be administered including anti-platelet agents like aspirin, cilostazol, dipyridamole and the like.
  • the antiplatelet agents may operate by a mechanism similar or different to the clopidogrel active metabolite to achieve desired levels of anti-platelet activity.
  • the second or subsequent anti-platelet agent may be administered separately, sequentially or simultaneously with a substantially pure (7aS,2′S)-2-oxo-clopidogrel or a pharmaceutically acceptable salt thereof.
  • a dose ranging from 20-100 mg of a substantially pure (7aS,2′S)-2-oxo-clopidogrel or a pharmaceutically acceptable salt be administered as an initial loading dose, and if necessary, a maintenance dose as low as 3-20 mg may subsequently be administered such that the systemic concentration of active metabolite is equal or greater than that amount obtained by administering a loading dose of 300-900 mg and a maintenance dose of 75-150 mg of clopidogrel, respectively. More preferably the loading dose of the present invention is between 20-80 mg and maintenance dose is between 5-15 mg. Still further lower doses may be administered, if the desired inhibition is equivalent or slightly inferior to that provided by clopidogrel.
  • the above doses are calculated for human of average body weight of 60 kgs. Dose adjustments may be necessary according to body weight of patients, severity of disease, genetic polymorphism of CYPs, at the discretion of the practitioner for the target platelet inhibition.
  • compositions for use in the methods discussed herein provides a fixed dose pharmaceutical composition comprising 1 mg to 60 mg of an isolated substantially pure (7aS,2′S)-2-oxo-clopidogrel or a pharmaceutically acceptable salt thereof and optionally one or more pharmaceutically acceptable excipients.
  • the fixed dose combination of the present invention may be administered along with one or more active compounds including antiplatelet/cardiovascular agent like aspirin, cilostazol etc. which may operate by a mechanism similar or other than clopidogrel active metabolite.
  • the inventive selection of the compounds of Formula IIA significantly contributes to improvements in the antiplatelet treatment compared to the use of clopidogrel and improves its therapeutic efficiency by about 5-10 times or more as well as reducing the associated toxicity/side effects or metabolic load associated with clopidogrel treatment.
  • the present invention can provide a therapeutically effective concentration of desired active metabolite isomer of clopidogrel in a short time after administration, which not only improves the onset of action but also achieves greater than 50% inhibition of ADP induced platelet aggregation.
  • the onset of action can be (as measured by 50% inhibition of ADP induced platelet aggregation) achieved in less than 1 hour, more preferably in 30 minutes, compared to 4-6 hours for clopidogrel.
  • the maximum platelet aggregation can be achieved in less than 1 hour after oral administration.
  • This invention also ameliorates the dose ceiling effect observed with higher doses of clopidogrel and provides significantly higher active metabolite output and reduced metabolic loading in liver.
  • clopidogrel is a P-Glycoprotein (Pgp) substrate
  • Pgp inhibitors or inducers which are likely to alter the clinical effects of clopidogrel.
  • This effect should also be reduced to a large extent by the administration of the compositions of the present invention.
  • the invention may permit the use of proton pump inhibitors in combination with Formula IIA.
  • compositions and methods of the present invention may reduce the toxicity and/or associated side effects observed due to the formation of clopidogrel acid (Formula IV) following clopidogrel administration.
  • the lethal dose of clopidogrel is about 5000 mg per kg in rat and 90% of clopidogrel is converted to clopidogrel acid in vivo.
  • it appears that around 90% of the toxicity of clopidogrel may be related to the clopidogrel acid metabolite (Formula IV).
  • compositions and methods of the present invention advantageously enable the amount of active ingredient administered to patients to be reduced, while also eliminating the formation of clopidogrel acid metabolite etc., following administration, the associated toxicity or adverse side effects will be reduced by at least 9-10 times compared to current clopidogrel therapeutic use.
  • the compounds employed in the compositions and methods according to present invention are preferably present in the form of their pharmaceutically acceptable salts.
  • acid addition salts include salts with mineral acids, especially hydrohalic acids (such as hydrofluoric acid, hydrobromic acid, hydroiodic acid or hydrochloric acid), nitric acid, carbonic acid, sulfuric acid; salts with lower alkylsulfonic acids, such as methanesulfonic acid, trifluoromethanesulfonic acid or ethanesulfonic acid; salts with arylsulfonic acids, such as benzenesulfonic acid or p-toluenesulfonic acid; and salts with organic carboxylic acids, such as acetic acid, propionic acid, butyric acid, fumaric acid, tartaric acid, oxalic acid, malonic acid, maleic acid, malic acid, succinic acid, benzoic acid, mandelic acid, ascorbic acid, lactic acid, gluconic
  • the methods and compositions of the present invention may further employ one or more active compounds including cardiovascular or antiplatelet agents such as aspirin, cilostazol, dipyridamole and the like which may operate by a mechanism similar or different to the clopidogrel active metabolite to achieve desired levels of anti-platelet activity.
  • the second or subsequent anti-platelet agent may be administered separately, simultaneously or subsequently with the compound of Formula IIA or as a pharmaceutically acceptable salt thereof.
  • the present invention encompasses such modifications thereof for achieving desired goal of inhibition of platelet aggregation.
  • the present invention provides a fixed dose pharmaceutical composition of compound of Formula IIA a pharmaceutically acceptable salts thereof wherein the dose of said compound of Formula IIA is selected from the range of 1 mg to 60 mg and the composition optionally comprises pharmaceutically acceptable excipients.
  • the fixed dose composition of the present invention may comprise or be administered along with one or more active compounds including antiplatelet/cardiovascular agents such as aspirin, cilostazol or the like which may operate by a mechanism similar or different to the clopidogrel active metabolite.
  • the fixed dose pharmaceutical compositions of the invention are preferably administered orally on a daily basis as an immediate release or modified release dosage form.
  • the dosage form may be formulated as a single unit dosage, as two separate unit dosages, and/or in any of the many variations known in the art, which include, but are not limited to, tablets, pills, hard capsules, soft capsules, pharmaceutical sachets and powders for reconstitution.
  • the formulations of the invention may further contain water insoluble permeable polymers, herein defined as “modified release polymers”, to adjust their release profile. These polymers may either be coated onto formulations such as tablets, microgranules, capsules or pills, or be mixed together with the other ingredients of any of the formulations listed above.
  • the pharmaceutical compositions of the present invention are provided in the form of tablets prepared by mixing the active agents with excipients.
  • excipients include diluents, fillers, binders, lubricants, disintegrants, glidants, colorants, pigments, taste masking agents, modified release polymers, sweeteners, plasticizers, and any acceptable auxiliary substances such as absorption enhancers, penetration enhancers, surfactants, co-surfactants, and specialized oils.
  • excipients include calcium phosphates, such as dibasic calcium phosphate, anhydrous dibasic calcium phosphate, tribasic calcium phosphate, etc.; microcrystalline cellulose, powdered cellulose; starch, pre-gelatinized starch; sodium starch glycolate; dextrates; mannitol, sorbitol; povidone; ethyl cellulose; lactose; kaolin; silicic acid; lubricants such as magnesium stearate, calcium stearate, stearic acid, mineral oil, glycerin, sodium lauryl sulfate, polyethylene glycol; and/or talc.
  • calcium phosphates such as dibasic calcium phosphate, anhydrous dibasic calcium phosphate, tribasic calcium phosphate, etc.
  • microcrystalline cellulose powdered cellulose
  • starch pre-gelatinized starch
  • sodium starch glycolate sodium starch glycolate
  • dextrates mannitol,
  • compositions of the present invention may be used to prepare compositions of the present invention to aid in tablet manufacture.
  • a premix of compound of Formula IIA may be obtained by mixing said compound with ingredients and thereafter either directly compressing the mixture into tablets or filling said mixture into capsules optionally along with other suitable ingredients to obtain final dosage form.
  • a unit dose of the free form of a compound of Formula IIA may be obtained as a granular premix by suitably processing that compound with acceptable ingredients such as polymers, which can be directly compressed or formulated with additional excipients.
  • compositions and methods of the present invention may be employed in the prevention and/or treatment of pathological states such as disorders of the cardiovascular and cerebrovascular system such as the thromboembolic disorders associated with atherosclerosis or with diabetes such as unstable angina, cerebral attack, restenosis following angioplasty, endarterectomy or fitting of metallic endovascular prostheses, with rethrombosis following thrombolysis, with infarction, with dementia of ischaemic origin, with peripheral arterial diseases, with haemodialyses, with auricular fibrillations or during the use of vascular prostheses or aortocoronary bypasses or in relation to stable or unstable angina.
  • pathological states such as disorders of the cardiovascular and cerebrovascular system such as the thromboembolic disorders associated with atherosclerosis or with diabetes such as unstable angina, cerebral attack, restenosis following angioplasty, endarterectomy or fitting of metallic endovascular prostheses, with rethrombosis following thrombolysis, with infarction, with dementia of is
  • the compounds of Formula II or its acid salts can be obtained by a method illustrated in the examples.
  • compositions of the invention demonstrate the properties of the compositions of the invention both from the point of view of toxicity and tolerance, and from the point of view of their activities, particularly inhibition of platelet and thrombotic aggregation.
  • compositions of the invention demonstrate excellent tolerance and low toxicity.
  • tests carried out on the acute, chronic, subchronic and delayed toxicities in different species of animals have not demonstrated any local or general reaction, disturbance or anomaly in the biochemical, macroscopic or microscopic examinations carried out during these experiments.
  • the platelet aggregation inhibiting activity and the toxicity of the inventive compositions were compared to those of the clopidogrel as per standard procedures reported in literature (Cardinal, D. C. and Flower, R. J. (1980) J. Pharm. Meth . Vol. 3, pp: 135-158; Ingerman-Wojenski et al. (1983) Thromb. Haemost . Vol. 51, pp: 154-156.).
  • the platelet aggregation inhibiting activities and the antithrombotic activities of the compounds were studied in the rats by standard methods.
  • the products as a suspension in 5% Gum Arabica (aq.) were administered by oral route to groups of six male rats of the SD strain, weighing 250-300 g.
  • 2 ml of blood is collected into the heparinized tubes by puncture of retro-orbital sinus.
  • 0.5 ml of the anticoagulated blood is diluted with an equal volume of isotonic saline solution and incubated at 37° C. for 10 minutes.
  • 10 ⁇ M ADP is added and the change in impedance (12), which reflects platelet aggregation, is recorded for 8 minutes with Chronolog Whole Blood Aggregometer (Model 592, Chrono-log Corp., USA).
  • the percentage inhibition of platelet aggregation is calculated by the following formula considering the vehicle control reading as 100%:
  • % ⁇ ⁇ Inhibition Impedence ⁇ ⁇ ( ⁇ ) ⁇ ⁇ in ⁇ ⁇ vehicle ⁇ ⁇ control - Impedance ⁇ ⁇ ( ⁇ ) ⁇ ⁇ in ⁇ ⁇ test ⁇ ⁇ compound Impedence ⁇ ⁇ ( ⁇ ) ⁇ ⁇ in ⁇ ⁇ Vehicle ⁇ ⁇ Control ⁇ 100
  • rats were anesthetized with Ketamine (100 mg/kg; i.p.), Xylazine (10 mg/kg; i.p) and placed on a heating pad.
  • Ketamine 100 mg/kg; i.p.
  • Xylazine 10 mg/kg; i.p
  • a midline incision of the tracheal area was made and a blunt dissection was performed to expose the common carotid artery.
  • % ⁇ ⁇ Inhibition Thrombus ⁇ ⁇ wt . ⁇ of ⁇ ⁇ vehicle ⁇ ⁇ control - Thrombus ⁇ ⁇ wt . ⁇ of ⁇ ⁇ test ⁇ ⁇ compound Thrombus ⁇ ⁇ weight ⁇ ⁇ of ⁇ ⁇ vehicle ⁇ ⁇ control ⁇ 100

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
US13/345,360 2011-06-27 2012-01-06 Anti-thrombotic compounds Abandoned US20120329762A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US13/428,657 US8536337B2 (en) 2011-06-27 2012-03-23 Solid forms of methyl (7aS,2′S)-2-(2-chlorophenyl)-2-(2,4,5,6,7,7a-hexahydrothieno[3,2-c]-5-pyridin-2-one)acetate
US13/957,119 US20130316987A1 (en) 2011-06-27 2013-08-01 Anti-Thrombotic Compounds
US13/956,945 US20130316986A1 (en) 2011-06-27 2013-08-01 Anti-Thrombotic Compounds
US14/045,430 US10105353B2 (en) 2011-06-27 2013-10-03 Anti-thrombotic compounds
US14/045,505 US20140038924A1 (en) 2011-06-27 2013-10-03 Anti-Thrombotic Compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1848MU2011 2011-06-27
ININ1848/MUM/2011 2011-06-27

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US13/428,657 Continuation US8536337B2 (en) 2011-06-27 2012-03-23 Solid forms of methyl (7aS,2′S)-2-(2-chlorophenyl)-2-(2,4,5,6,7,7a-hexahydrothieno[3,2-c]-5-pyridin-2-one)acetate
US14/045,430 Continuation US10105353B2 (en) 2011-06-27 2013-10-03 Anti-thrombotic compounds
US14/045,505 Continuation US20140038924A1 (en) 2011-06-27 2013-10-03 Anti-Thrombotic Compounds

Publications (1)

Publication Number Publication Date
US20120329762A1 true US20120329762A1 (en) 2012-12-27

Family

ID=45495857

Family Applications (6)

Application Number Title Priority Date Filing Date
US13/345,360 Abandoned US20120329762A1 (en) 2011-06-27 2012-01-06 Anti-thrombotic compounds
US13/428,657 Active US8536337B2 (en) 2011-06-27 2012-03-23 Solid forms of methyl (7aS,2′S)-2-(2-chlorophenyl)-2-(2,4,5,6,7,7a-hexahydrothieno[3,2-c]-5-pyridin-2-one)acetate
US13/956,945 Abandoned US20130316986A1 (en) 2011-06-27 2013-08-01 Anti-Thrombotic Compounds
US13/957,119 Abandoned US20130316987A1 (en) 2011-06-27 2013-08-01 Anti-Thrombotic Compounds
US14/045,430 Expired - Fee Related US10105353B2 (en) 2011-06-27 2013-10-03 Anti-thrombotic compounds
US14/045,505 Abandoned US20140038924A1 (en) 2011-06-27 2013-10-03 Anti-Thrombotic Compounds

Family Applications After (5)

Application Number Title Priority Date Filing Date
US13/428,657 Active US8536337B2 (en) 2011-06-27 2012-03-23 Solid forms of methyl (7aS,2′S)-2-(2-chlorophenyl)-2-(2,4,5,6,7,7a-hexahydrothieno[3,2-c]-5-pyridin-2-one)acetate
US13/956,945 Abandoned US20130316986A1 (en) 2011-06-27 2013-08-01 Anti-Thrombotic Compounds
US13/957,119 Abandoned US20130316987A1 (en) 2011-06-27 2013-08-01 Anti-Thrombotic Compounds
US14/045,430 Expired - Fee Related US10105353B2 (en) 2011-06-27 2013-10-03 Anti-thrombotic compounds
US14/045,505 Abandoned US20140038924A1 (en) 2011-06-27 2013-10-03 Anti-Thrombotic Compounds

Country Status (13)

Country Link
US (6) US20120329762A1 (zh)
EP (2) EP2675813A4 (zh)
JP (1) JP2014518260A (zh)
KR (1) KR20140047082A (zh)
CN (1) CN104245707A (zh)
AU (1) AU2012277327B2 (zh)
BR (1) BR112013033464A2 (zh)
CA (1) CA2839608C (zh)
MX (1) MX344435B (zh)
RU (1) RU2604733C2 (zh)
SG (1) SG195257A1 (zh)
WO (1) WO2013001544A1 (zh)
ZA (1) ZA201309411B (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150174082A1 (en) * 2012-06-01 2015-06-25 Bayer Technology Services Gmbh Genotype- or phenotype-based drug formulation
CN111943958A (zh) * 2019-05-17 2020-11-17 成都施贝康生物医药科技有限公司 四氢噻吩并吡啶化合物的b晶型及制法、组合物和应用

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107698620A (zh) 2015-06-23 2018-02-16 江苏天士力帝益药业有限公司 一种氘代噻吩并哌啶衍生物、制备方法及其应用
CN107304215A (zh) * 2016-04-20 2017-10-31 陕西合成药业股份有限公司 噻吩吡啶类衍生物及其制备方法和用途
CN108685913B (zh) * 2018-07-31 2021-08-10 成都施贝康生物医药科技有限公司 含氧吡格雷光学异构体或其盐的组合物及制备方法和应用
CN109912595B (zh) * 2019-03-29 2020-08-25 成都施贝康生物医药科技有限公司 一种抗炎药物及其用途
CN112076190B (zh) * 2019-06-14 2023-04-07 成都施贝康生物医药科技有限公司 一种含有难溶性噻吩并吡啶组合物的固体制剂及制备方法
WO2021070200A2 (en) * 2019-10-08 2021-04-15 Ipca Laboratories Limited Stable compositions of (7as,2's)-2-oxoclopidogrel and its pharmaceutical salts
CN111138450B (zh) * 2020-01-19 2024-04-19 成都施贝康生物医药科技有限公司 一种抗炎化合物及其制法和用途
CN111150731A (zh) * 2020-01-19 2020-05-15 成都施贝康生物医药科技有限公司 含氧吡格雷光学异构体或其盐的组合物及应用
CN111249241B (zh) * 2020-01-19 2023-06-27 成都施贝康生物医药科技有限公司 一种含有难溶性噻吩并吡啶组合物的固体制剂及制备方法
CN115327003B (zh) * 2022-08-12 2024-03-12 成都施贝康生物医药科技有限公司 一种氧化氯吡格雷有关物质的检测方法
CN115327004B (zh) * 2022-08-12 2024-01-26 成都施贝康生物医药科技有限公司 一种氧化氯吡格雷粗品的检测方法
CN115429797A (zh) * 2022-08-31 2022-12-06 成都施贝康生物医药科技有限公司 一种含氧氯吡格雷或其盐的组合物及其制备

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4740510A (en) * 1985-01-31 1988-04-26 Sanofi (S.A.) Derivatives of alpha-(2-oxo 2,4,5,6,7,7a-hexahydro thieno[3,2-c]5-pyridyl) phenyl acetic acid, and their use as platelet and thrombotic aggregation inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2530247B1 (fr) 1982-07-13 1986-05-16 Sanofi Sa Nouveaux derives de la thieno (3, 2-c) pyridine, leur procede de preparation et leur application therapeutique
FR2623810B2 (fr) 1987-02-17 1992-01-24 Sanofi Sa Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant
FR2652579B1 (fr) * 1989-10-02 1992-01-24 Sanofi Sa Derives d'hydroxy-2 thiophene et furanne condenses avec un cycle azote, sur procede de preparation et leur application en therapeutique.
JPH10310586A (ja) * 1996-06-26 1998-11-24 Sankyo Co Ltd ヒドロピリジン類の新規医薬用途
FR2779726B1 (fr) 1998-06-15 2001-05-18 Sanofi Sa Forme polymorphe de l'hydrogenosulfate de clopidogrel
TWI392681B (zh) * 2006-04-06 2013-04-11 Daiichi Sankyo Co Ltd 高純度普拉格雷及其酸加成鹽之製法
CN101885730B (zh) * 2009-05-13 2012-07-04 连云港恒邦医药科技有限公司 抗血栓的化合物
CN102863457B (zh) * 2010-02-02 2013-10-09 江苏威凯尔医药科技有限公司 光学活性2-羟基四氢噻吩并吡啶衍生物及其制备方法与在制药中的用途
CN102212069A (zh) * 2010-04-06 2011-10-12 刘桂坤 环烷衍生物及其制备方法和在心脑血管病药物上的应用
CN102212068A (zh) * 2010-04-06 2011-10-12 刘桂坤 噻吩衍生物及其制备方法和在药物上的应用
RU2611662C2 (ru) * 2010-08-26 2017-02-28 Ипка Лэборэториз Лимитед Способы лечения или профилактики тромбообразования или эмболии

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4740510A (en) * 1985-01-31 1988-04-26 Sanofi (S.A.) Derivatives of alpha-(2-oxo 2,4,5,6,7,7a-hexahydro thieno[3,2-c]5-pyridyl) phenyl acetic acid, and their use as platelet and thrombotic aggregation inhibitors

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"Happy Birthday!" Chromatographia 2008, 67, January (No. 1/2). *
Harrold, M.W. and Zavod, R.M. "Medicinal Chemistry" ASHP: Bethesda, 2013, Chapter 7. *
Kozma "CRC handbook of optical resolutions via diastereomeric salt formation I" CRC press:2002, Pages 3-5. *
Savi "Identification and Biological Activity of the Active Metabolite of Clopidogrel." Thromb Haemost 2000; 84: 891-6. *
Testa "The Biochemistry of Drug Metabolism - An Introduction Part 5. Metabolism and Bioactivity." CHEMISTRY & BIODIVERSITY - Vol. 6 (2009) 591-683. *
Wainer, Irving P. "Drug Stereochemistry: analytical methods and pharmacology" Macel Dekker New York: 1993, pages 29-30. *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150174082A1 (en) * 2012-06-01 2015-06-25 Bayer Technology Services Gmbh Genotype- or phenotype-based drug formulation
US10285958B2 (en) * 2012-06-01 2019-05-14 Bayer Aktiengesellschaft Genotype- or phenotype-based drug formulation
CN111943958A (zh) * 2019-05-17 2020-11-17 成都施贝康生物医药科技有限公司 四氢噻吩并吡啶化合物的b晶型及制法、组合物和应用
WO2020233226A1 (zh) * 2019-05-17 2020-11-26 成都施贝康生物医药科技有限公司 四氢噻吩并吡啶化合物的b晶型及制法、组合物和应用

Also Published As

Publication number Publication date
US20130316986A1 (en) 2013-11-28
ZA201309411B (en) 2014-08-27
US20140031320A1 (en) 2014-01-30
WO2013001544A1 (en) 2013-01-03
SG195257A1 (en) 2013-12-30
US8536337B2 (en) 2013-09-17
EP2675813A4 (en) 2014-04-30
JP2014518260A (ja) 2014-07-28
EP2675813A1 (en) 2013-12-25
BR112013033464A2 (pt) 2017-01-24
RU2604733C2 (ru) 2016-12-10
CN104245707A (zh) 2014-12-24
KR20140047082A (ko) 2014-04-21
AU2012277327A1 (en) 2014-01-09
US10105353B2 (en) 2018-10-23
NZ618694A (en) 2016-03-31
CA2839608C (en) 2020-07-14
MX2013014946A (es) 2014-02-17
EP2540729A1 (en) 2013-01-02
RU2014102362A (ru) 2015-08-10
MX344435B (es) 2016-12-14
AU2012277327B2 (en) 2017-04-27
US20140038924A1 (en) 2014-02-06
CA2839608A1 (en) 2013-01-03
US20120329763A1 (en) 2012-12-27
US20130316987A1 (en) 2013-11-28
WO2013001544A9 (en) 2014-09-12

Similar Documents

Publication Publication Date Title
US8536337B2 (en) Solid forms of methyl (7aS,2′S)-2-(2-chlorophenyl)-2-(2,4,5,6,7,7a-hexahydrothieno[3,2-c]-5-pyridin-2-one)acetate
US8541422B2 (en) Methods for the treatment or prophylaxis of thrombosis or embolism
EP2112155B1 (en) Hydrogensulfate salt of 2-acetoxy-5-(a-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine and its preparation
KR20180016631A (ko) 광학활성 2-히드록시테트라히드로티에노피리딘 유도체 및 그 제조방법과 제약적 용도
JP5575979B2 (ja) シアノ基を含有するチエノピリジンエステル誘導体、その調製方法、使用および組成物
NZ618694B2 (en) Anti-thrombotic compounds
KR20140000717A (ko) 신규한 항-혈소판 화합물의 부가염
RU2526624C2 (ru) Производное сложного эфира тиенопиридина, содержащее цианогруппу, способ его получения, его применение и композиция на его основе

Legal Events

Date Code Title Description
AS Assignment

Owner name: IPCA LABORATORIES LIMITED, INDIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KUMAR, ASHOK;SOUDAGAR, SATISH RAJANIKANT;BYJU, NELLITHANATH THANKACHEN;AND OTHERS;REEL/FRAME:027602/0310

Effective date: 20120124

STCV Information on status: appeal procedure

Free format text: NOTICE OF APPEAL FILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STCV Information on status: appeal procedure

Free format text: NOTICE OF APPEAL FILED

STCV Information on status: appeal procedure

Free format text: APPEAL BRIEF (OR SUPPLEMENTAL BRIEF) ENTERED AND FORWARDED TO EXAMINER

STCV Information on status: appeal procedure

Free format text: EXAMINER'S ANSWER TO APPEAL BRIEF MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION